杏丁注射液治疗慢性肾衰竭患者的临床研究  

Clinical trial of Xingding injection in the treatment of chronic renal failure patients

作　　者：俞凯[1] 张旗[1] 董金胜[1] 傅裕[1] 罗璟[1] 

机构地区：[1]滁州市中西医结合医院肾脏科,安徽滁州239000

出　　处：《中国临床药理学杂志》2016年第22期2046-2048,2055,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家"重大新药创制"科技重大专项基金资助项目(2011ZX09303-001)

摘　　要：目的观察杏丁注射液对慢性肾衰竭患者的临床疗效及其对血清脂联素、胱抑素C及β2微球蛋白的影响。方法 76例慢性肾衰竭患者随机分为对照组与试验组,各38例。对照组给予降压、调脂等对症治疗,控制血压、血脂稳定;试验组在对照组的基础上静脉滴注杏丁注射液20 mg,每天1次。2组均治疗14d。比较2组患者的临床疗效,观察2组血清脂联素、白细胞介素^(-1)0(IL^(-1)0)、肿瘤坏死因子-α(TNF-α)、血肌酸酐(Scr)、胱抑素C、β2微球蛋白水平和药物不良反应发生情况。结果治疗后,试验组总有效率为84.21%(32/38例),对照组为63.16%(24/38例,P<0.05)。治疗后,对照组和试验组脂联素分别为(16.26±2.17),(9.78±1.29)mg·L^(-1),TNF-α分别为(22.68±3.26),(15.83±2.32)pg·m L^(-1),IL^(-1)0分别为(27.32±3.51),(18.16±2.32)pg·m L^(-1),Scr分别为(325.18±47.32),(293.68±43.27)μmol·L^(-1),胱抑素C分别为(3.78±0.53),(3.51±0.51)mg·L^(-1),β2微球蛋白分别为(6.52±0.93),(6.06±0.87)mg·L^(-1),差异均有统计学意义(P<0.05)。对照组出现恶心1例,腹泻3例,头晕2例,药物不良反应发生率为15.79%(6/38例);试验组出现恶心1例,腹泻2例,头晕3例,皮肤过敏1例,药物不良反应发生率为18.42%(7/38例),差异无统计学意义(P>0.05)。结论杏丁注射液能降低慢性肾衰竭患者血清炎症因子水平,提高肾小球滤过功能,改善临床症状,且安全性较高。Objective To evaluate the clinical efficacy of Xingding injection in the treatment of chronic renal failure and its effect on adiponectin, cystatin C （Cys -C ） and β2 microglobulin （β2 -MG）. Methods A total of 76 chronic renal failure patients were randomly divided into control group and treatment group, 38 cases in each group. Control group was treated with symptomatic treatment, such as lowering blood pressure, regulating fat, controlling blood pressure and blood lipid. Treatment group was given Xingding dipyridamole injection 20 mg on the basis of control group. All patients were treated for 14 d. Serum adiponectin （ ADPN ）, tumor necrosis factor - α （ TNF - α ）, interleukin - 10（ IL - 10） , serum creatinine （Scr） , Cys - C, β2 - MG, clinical efficacy and adverse drug reactions were compared in two groups. Results The clinical effective rate was 84.21% （32/38） in treatment group, had significant difference with control group, which was 63.16% （24/38, P 〈0.05 ）. After treatment, ADPN in control and the treatment group were （16.26±2.17）,（9.78±1.29） mg . L-1, TNF-α were（22. 68 ±3.26）, （15.83 ±2.32） pg .mL-1,IL- 10 were （27.32 ±3.51） ,（18.16 ±2. 32） pg . mL-1, Scr were （325. 18±47.32）, （293.68 ±43.27） μ mol . L-1, Cys-C were （3.78±0.53）, （3.51 ±0.51） mg . L-1, β2 - MG were （6.52 ± 0. 93 ）, （6.06 ± 0. 87 ） mg .L - 1 （ p 〈 0. 05 ）. In control group, there were 1 case of nausea, 3 cases of diarrhea, 2 cases of dizziness, the incidence of adverse drug reactions was 15.79% （6/38）. In treatment group, there were 1 case of nausea, 2 cases of diarrhea, 3 cases of dizziness, 1 case of skin allergies, the incidence rate of adverse drug reactions was 18.42% （7/38, P 〉 0. 05 ）. Conclusion Xingding injection can reduce the levels of serum inflammatory cytokines in patients with chronic renal failure, improve glomerular filtration function and clinical symptoms, with high safety.

关 键 词：杏丁注射液 慢性肾衰竭 脂联素 胱抑素C Β2微球蛋白 

分 类 号：R285[医药卫生—中药学]